Fig. 2
From: Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report
Levels of mutations in ctDNA and total cfDNA level in serial samples during disease progression. The allele frequency of mutations in COL2A1, NF1, PTGS2, LRP2, KRAS and PRRC2C was quantified in primary tumour (squares) at time of surgery (0d) and in serial plasma samples (circles) collected one day (−1d) before surgery, three days (3d) and six weeks (6w) after surgery using targeted resequencing. The total level of cfDNA (normal and tumour) was quantified in plasma samples (hexagon) using Qubit fluorometer. Distal metastases were identified after six weeks (6w), and the patient succumbed to the disease after 13 weeks (13w) with aggressive metastatic disease